论文部分内容阅读
胃癌是死亡率最高的肿瘤之一。对于晚期胃癌,化疗仍是其主要的治疗手段。但是目前为止尚无标准方案。根据临床研究的进展,我们应该进一步优化化疗策略。单药化疗有效率低,不推荐用于常规化疗,但由于毒性较小,仍适用于体质状况差、无法耐受强烈化疗的患者,同时可尝试用于强烈化疗间歇期的维持治疗。两药联合化疗有效率明显高于单药化疗,同时毒副反应发生率低于三药联合,适用于大多数患者。三药联合化疗毒性反应强烈,但近期有效率最高,适用于体质较好或希望获得高有效率的患者。很多分子靶向药物已经在临床研究和应用中显示出良好的效果和治疗前景,但仍需在临床研究和实践中进一步调整和优化。
Gastric cancer is one of the most deadly tumors. For advanced gastric cancer, chemotherapy is still its main treatment. But so far there is no standard solution. Based on the progress of clinical research, we should further optimize the chemotherapy strategy. Chemotherapy with monotherapy is ineffective and is not recommended for routine chemotherapy. However, due to its low toxicity, it is still suitable for patients who are in poor physical condition and can not tolerate intensive chemotherapy. At the same time, they can try to maintain the intermittent period of intensive chemotherapy. The combination of two drugs was significantly higher than the single chemotherapy efficiency, while the incidence of side effects less than three drugs, suitable for most patients. Three drugs combined with strong toxicity of chemotherapy, but the most effective recently, for better physical fitness or hope to obtain high efficiency in patients. Many molecular targeted drugs have shown good efficacy and therapeutic prospect in clinical research and application, but still need to be further adjusted and optimized in clinical research and practice.